ViewpointDefined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin
References (18)
- et al.
Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia
Lancet
(1986) - et al.
Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia.
Atherosclerosis
(1992) Anatomical therapeutic chemical classification index
(1994)- et al.
Expanded clinical evaluation of lovastatin (EXCEL) study results
Arch Intern Med
(1991) - et al.
Comparative efficacy of once daily versus twice daily pravastatin in primary hypercholesterolaemia
Clin Ther
(1991) - et al.
Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia
J Clin Invest
(1984) - et al.
Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multi-center study
Ann Intern Med
(1987) - et al.
Treatment of familial hypercholesterolemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels
J Intern Med
(1990)
Cited by (80)
Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3β phosphorylation
2016, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Statins are the most effective drugs in lowering plasma cholesterol and prevention of cardiovascular disease [1].
Simvastatin inhibits glucose uptake activity and GLUT4 translocation through suppression of the IR/IRS-1/Akt signaling in C2C12 myotubes
2016, Biomedicine and PharmacotherapyCitation Excerpt :These findings suggest that the impairment of GLUT4 translocation induced by simavstain may be associated with decrease in Rac1-GTP activity. Statins are inhibitors of hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase, which can inhibit the synthesis of endogenouse cholesterol [1]. It has been demonstrated that statins are associated with the risk of new-onset diabetes in long-term therapy [2,6], but the underlying mechanism remains perplexing.
Effects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolemia: A randomized, open-label trial
2002, Current Therapeutic Research - Clinical and ExperimentalExpression of an endothelial-type nitric oxide synthase isoform in human neutrophils: Modification by tumor necrosis factor-alpha and during acute myocardial infarction
2001, Journal of the American College of CardiologyCitation Excerpt :This was accompanied by an increased expression of eNOS protein, suggesting an association between the binding of cytosolic proteins to the 3′-UTR of eNOS mRNA and the decrease in eNOS protein expression. The levels of simvastatin that prevented eNOS protein expression in TNF-alpha–stimulated neutrophils are within the range of the expected tissue levels obtained with recommended doses (33). It is noteworthy that the binding region of the neutrophil cytosolic proteins flanks a potential stem-loop structure in the 3′-UTR of eNOS mRNA.
Comparison of different methods to estimate prevalence of drug use by using pharmacy records
2001, Journal of Clinical EpidemiologyHmg-coa reductase inhibitors
2001, Advances in Protein Chemistry